Nanofiltration of single plasma donations: feasibility study

Background and Objectives Major technical developments have been made in recent years to improve the quality and safety of human plasma for transfusion and fractionation. The present study was performed to assess, for the first time, the feasibility of applying a nanofiltration process, using 75‐nm and 35‐nm mean pore size membranes (Planova® 75N and Planova® 35N), to human plasma.

[1]  R. Rubenstein,et al.  A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins , 2001, Transfusion.

[2]  W. Drohan,et al.  Viral inactivation of vesicular stomatitis virus in normal human serum by cross-linked polyvinylpyrrolidone. , 1993, The Journal of infectious diseases.

[3]  K. Reid,et al.  Inactivation of Viruses during Ultraviolet Light Treatment of Human Intravenous Immunoglobulin and Albumin , 1993, Vox sanguinis.

[4]  久實 池田,et al.  再生セルロース中空糸 (BMM) を用いた人血漿からのB型肝炎ウイルス除去の可能性 , 1989 .

[5]  J. Montoro,et al.  Factor VIII/von Willebrand factor complex in methylene blue‐treated fresh plasma , 1999, Transfusion.

[6]  K. Kamide,et al.  Some Morphological Characteristics of Porous Polymeric Membranes Prepared by “Micro-Phase Separation Method” , 1987 .

[7]  J. Huart,et al.  A pasteurized therapeutic plasma. , 1992, Infusionstherapie und Transfusionsmedizin.

[8]  W. Hiddemann,et al.  Contamination of fresh‐frozen plasma with viable white cells and proliferable stem cells , 1994, Transfusion.

[9]  C. Prowse,et al.  A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco‐Tronic system , 2001, Transfusion medicine.

[10]  J. Huart,et al.  Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI Concentrates , 1994, Vox sanguinis.

[11]  A. Losikoff,et al.  Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[12]  L. McShane,et al.  Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humans , 1999, Transfusion.

[13]  R. Cardigan,et al.  The effect of leucocyte depletion on the quality of fresh‐frozen plasma , 2001, British journal of haematology.

[14]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[15]  M. Turner,et al.  Distribution of cell‐associated prion protein in normal adult blood determined by flow cytometry , 1999, British journal of haematology.

[16]  P. Brown.  Transfusion medicine and spongiform encephalopathy , 2001, Transfusion.

[17]  B. Horowitz,et al.  Virus Inactivation by Solvent/Detergent Treatment and the Manufacture of SD‐Plasma , 1998, Vox sanguinis.

[18]  C. Prowse,et al.  Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus‐inactivated plasma , 2000, British journal of haematology.

[19]  C. Prowse,et al.  The release of prion protein from platelets during storage of apheresis platelets , 2001, Transfusion.

[20]  D. Huhn,et al.  The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single‐donor fresh‐frozen plasma , 1994, Transfusion.

[21]  H. Schwarz,et al.  Comparative Study on Collagen-Binding Enzyme-Linked Immunosorbent Assay and Ristocetin Cofactor Activity Assays for Detection of Functional Activity of von Willebrand Factor , 2002, Seminars in thrombosis and hemostasis.

[22]  Michael J. Bernstein.  Fresh Frozen Plasma: Indications and Risks , 1987 .

[23]  M. Turner,et al.  New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. , 1998, Blood reviews.

[24]  M. Horowitz,et al.  SD Plasma in TTP and Coagulation Factor Deficiencies for which no Concentrates are Available , 1998, Vox sanguinis.

[25]  J. Goudemand,et al.  A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate , 1998, Thrombosis and Haemostasis.

[26]  P. Roberts.  Value of Virus Filtration as a Method for Improving the Safety of Plasma Products , 1995, Vox sanguinis.

[27]  B. Boneu,et al.  Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. , 1992, Nouvelle revue francaise d'hematologie.

[28]  H. Nielsen,et al.  Leucocyte-derived bioactive substances in fresh frozen plasma. , 1997, British journal of anaesthesia.

[29]  K. Hiruma,et al.  Effect of leucocyte reduction on the potential alloimmunogenicity of leucocytes in fresh‐frozen plasma products , 2001, Vox sanguinis.

[30]  A. Brand.  Immunological aspects of blood transfusions. , 2002, Transplant immunology.

[31]  T. Burnouf,et al.  Nanofiltration of plasma‐derived biopharmaceutical products , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  B. Griffin,et al.  Studies on the Removal of Abnormal Prion Protein by Processes Used in the Manufacture of Human Plasma Products , 2000, Vox sanguinis.

[33]  P. Gottlieb,et al.  Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. , 1995, Blood.

[34]  B. Lambrecht,et al.  Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible Light , 1991, Vox sanguinis.

[35]  S. Mohri,et al.  Scrapie removal using Planova virus removal filters. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[36]  F. Leebeek,et al.  Coagulation factor levels in solvent/detergent‐treated plasma , 1999, Transfusion.

[37]  P. Brown,et al.  The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy , 1998, Transfusion.

[38]  T Burnouf,et al.  Reducing the risk of infection from plasma products: specific preventative strategies. , 2000, Blood reviews.

[39]  T. Burnouf,et al.  Virucidal heat‐treatment of single plasma units: a potential approach for developing countries , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  哲之 北本,et al.  クロイツフェルトヤコブ病 (CJD) の原因物質の膜除去方法 , 1993 .

[41]  Prowse,et al.  Preliminary assessment of whole‐blood, red‐cell and platelet‐ leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing , 1999, British journal of haematology.